Medtronic plc

Medtronic plc (NYSE: MDT) is the leading global healthcare technology company, headquartered in Ireland and serving healthcare systems, physicians, clinicians, and patients in more than 150 countries worldwide. Founded in 1949, the company operates with a mission to alleviate pain, restore health, and extend life through the application of biomedical engineering. More information about the company is available at www.medtronic.com.

The company operates three primary reportable segments: the Cardiovascular Portfolio, the Neuroscience Portfolio, and the Medical Surgical Portfolio. The Cardiovascular Portfolio encompasses cardiac rhythm management, structural heart and aortic therapies, and coronary and peripheral vascular solutions. The Neuroscience Portfolio includes cranial and spinal technologies, specialty therapies for stroke and neurological conditions, and neuromodulation systems for chronic pain and brain modulation. The Medical Surgical Portfolio comprises surgical and endoscopy products alongside acute care and monitoring solutions. In March 2026, Medtronic completed the initial public offering of its Diabetes Business, which was separated as MiniMed Group, Inc.

Medtronic employs over 95,000 full-time employees globally, with 43 percent based in the United States or Puerto Rico. The company manufactures products at facilities located throughout the world and maintains a global distribution network combining direct sales representatives and third-party distributors.

The company's product portfolio includes implantable cardiac devices, surgical instruments, robotic-assisted surgery systems, neurovascular products, spinal implants, and patient monitoring systems. Notable brands and technologies include the Azure pacemaker line, CoreValve aortic valve systems, Hugo robotic-assisted surgery platform, Evolut transcatheter aortic valve replacement systems, and various neuromodulation and spinal cord stimulation devices.

Medtronic's competitive advantages include extensive intellectual property protections, established relationships with healthcare providers and institutions, advanced manufacturing capabilities, and a robust research and development pipeline addressing unmet clinical needs. The company pursues innovation through internal development, strategic acquisitions, licensing arrangements, and external collaborations to maintain technological leadership across its diverse therapeutic markets.